Nov 2026· Cellular Signalling· pp.
112970
· 0 citations· 54 references
Medicine
TL;DR
SSBP1, a mitochondrial-localized protein associated with LUAD patient prognosis, promotes LUAD progression by inhibiting ferroptosis through the ERK/NRF2/GPX4 axis.
Abstract
Background
Lung adenocarcinoma (LUAD) accounts for roughly half of all lung cancer cases and novel therapeutic targets remain scarce. Ferroptosis, an iron-dependent form of regulated cell death, offers a promising strategy to combat therapy resistance. Mitochondrial single-stranded DNA-binding protein 1 (SSBP1) is critical for mitochondrial genome stability, but its role in ferroptosis and LUAD progression remains undefined.
Methods
We analyzed SSBP1 expression and prognostic value in LUAD using public datasets and clinical specimens. In vitro, we used SSBP1 knockdown/overexpression in LUAD cell lines to assess cell viability, ferroptosis markers (Fe2+, Lipid ROS, MDA, rescue experiments), and mitochondrial function. Transcriptomic sequencing, GSEA, and Western blot were employed to identify the underlying pathway. The therapeutic potential of SSBP1 inhibition combined with the ferroptosis inducer RSL3 was validated in vitro and in a xenograft mouse model.
Results
High SSBP1 expression is associated with patient prognosis and restrains lipid peroxidation by sustaining ERK-dependent NRF2 nuclear translocation and subsequent HO-1 and GPX4 expression. Loss of SSBP1 impairs this antioxidant signaling axis, leading to increased ferrous ions and lipid ROS within LUAD cells, ultimately sensitized LUAD cells to RSL3, significantly enhancing ferroptosis and inhibiting tumor growth in vivo. Furthermore, mitochondrial damage resulting from ferroptosis in cancer cells exacerbates the mitochondrial apoptosis pathway induced by SSBP1 dysregulation.
Conclusion
SSBP1, a mitochondrial-localized protein associated with LUAD patient prognosis, promotes LUAD progression by inhibiting ferroptosis through the ERK/NRF2/GPX4 axis.
Background Ferroptosis has emerged as a potential avenue for cancer therapy; however, the molecular mechanisms regulating ferroptosis resistance in osteosarcoma (OS) remain incompletely understood. This study aimed to investigate the role of targeting protein for Xklp2 (TPX2) in OS progression and ferroptosis, focusing...
Hua-Shun Liu, Lan-Jun Tang, Biao Chen et al.· Journal of Bone Oncology· 0 citations
A KLF5-G6PD-SLC7A11 axis is identified as a critical metabolic safeguard against ferroptosis in LUSC, and targeting G6PD disrupts mitochondrial homeostasis, enhances mitophagy-dependent oxidative stress, and sensitizes tumors to ferroptotic therapy, highlighting a promising therapeutic strategy for LUSC.
Nan-Ding Yu, Ying-Xiao Wu, Meng-Ling Li et al.· International Immunopharmaco...· 0 citations
Non-small cell lung cancer (NSCLC) remains a challenging disease due to its high heterogeneity and the lack of effective treatment strategies. Ferroptosis, a recently identified form of regulated cell death driven by the accumulation of lipid hydroperoxides, has emerged as a promising therapeutic strategy in NSCLC. W...
Xue-Ping Lei, Jie-Yao Liu, Ji-Hong Gu et al.· Cell Death & Disease· 0 citations
Background: Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide, and novel therapeutic strategies are urgently needed to overcome treatment resistance. Cordycepin (Cor), a bioactive nucleoside isolated from Cordyceps militaris, exhibits antitumor activity in multiple maligna...
Ya-Chun Guo, Jia-Hui Zhang, Yan-Chao Li· International Journal of Pha...· 0 citations
Abstract Ferroptosis is a regulated form of cell death driven by iron‐dependent lipid peroxidation and has emerged as a promising therapeutic target in nonsmall cell lung cancer (NSCLC). However, the specific mechanisms by which nonsmall cell lung cancer cells evade ferroptosis remain to be further elucidated. We condu...
Xin Fan, Yu-Biao Lin, Zhi-Gao Zhen et al.· Journal of cell communicatio...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.